ALZAI Health Signs Alzheimer's MOU With Quanterix
The non-binding memorandum explores combining AI-driven risk identification with blood-based biomarker testing for earlier detection.
Updated on Nov. 13, 2026 in Alzheimer’s
ALZAI Health Corp. entered into a Memorandum of Understanding with Quanterix Corporation to explore collaboration on earlier identification and assessment of Alzheimer's disease. The MOU was announced on November 13, 2026, and is primarily non-binding, with any future commercial arrangements subject to separate definitive agreements.
Why it matters
The proposed collaboration would pair an AI-driven risk identification tool with blood-based biomarkers, aiming to help clinicians identify individuals at elevated risk for Alzheimer's disease sooner. For Canadian readers, the agreement signals growing interest in less invasive early-detection approaches for a disease that affects patients and health systems across the country.
The announcement is a non-binding corporate memorandum and discloses no efficacy, sample-size or cost figures. Key details on any final agreement, clinical validation or commercial terms remain unreported.
The players
ALZAI Health Corp.
A healthcare technology company developing AI-driven solutions for identifying disease risk, including Alzheimer's disease, and based in Toronto, Ontario.
Quanterix Corporation
A life sciences company focused on ultra-sensitive biomarker detection and blood-based diagnostic testing, and the developer of the LucentAD blood-based biomarker test.
The details
The companies intend to explore opportunities with healthcare providers, health systems and other healthcare organizations, combining ALZAI's AI-driven Alzheimer's risk identification technology with Quanterix's LucentAD blood-based biomarkers. ALZAI describes itself as a healthcare technology company developing AI-driven disease risk identification solutions, while Quanterix focuses on ultra-sensitive biomarker detection and blood-based diagnostic testing.
Timeline
November 13, 2026: ALZAI Health Corp. announced the Memorandum of Understanding with Quanterix Corporation.
Health Landscape
The collaboration builds on the shift toward blood-based biomarker tests such as Quanterix's LucentAD, which aim to offer an alternative to more costly and invasive diagnostic methods for Alzheimer's disease. Pairing such tests with AI-driven risk tools reflects a broader move toward earlier, population-level identification of at-risk patients.
For patients concerned about memory decline, the collaboration points toward earlier risk assessment that could lead to more targeted testing with a physician. The MOU is non-binding, so no new test or service is available to Canadian patients as a result of this announcement.
The takeaway
Patients and caregivers should treat this announcement as an early corporate step rather than a new clinical option. Anyone with concerns about memory changes should discuss screening and testing options with a healthcare provider.
Further reading
For more on the disease at the centre of this agreement, explore Alzheimer’s coverage on Wisevoter.
Source note: This article includes information reported by Timmins Daily Press.
